Cervical cancer In 2009, the International Federation of Gynecology and Obstetrics (FIGO) divided stage IIA cervical cancer into stage IIA1 (≤4 cm) and stage IIA2 (>4 cm). The new edition of the Guidelines has updated this accordingly and highlighted the role of imaging in guiding the treatment of cervical cancer. Positron emission tomography (PET)-CT for cervical cancer screening has a sensitivity of 83% to 100% and a specificity of 92%, which can help detect isolated recurrent or persistent treatable lesions. Radiotherapy The new version of the Guidelines states that radiotherapy is an important tool in the treatment of cervical cancer, including external irradiation and brachytherapy. The external radiation dose is the sum of the traditional single split dose (45-50 Gy), and the anterior field border should include the area where the tumor may spread to the body of the uterus, the posterior field border includes the area where the tumor may spread to the uterosacral ligament and the presacral lymph nodes, and the lateral field border should include sufficient pelvic lymph nodes. For patients whose tumor invades the lower third of the vagina, inguinal lymph nodes should be within the treatment area. In contrast, extended field radiotherapy to the para-aortic lymph nodes should be planned in detail to ensure that the dose is adequate and tolerated by the intestine, spinal cord, or kidneys. In the case of brachytherapy, due to the uneven dose distribution in the pelvis, a clinically significant point (so-called reference point) should be selected for dose determination. Inconsistencies in the reference point can affect dose and efficacy, and it is important to determine a common reference point location. The International Commission on Radiation Units and Measurements (ICRU) Report 38 redefined the location of point A, the end of the intrauterine radiation source, at the cervical orifice site, 2 cm above the uterine orifice and 2 cm next to the cervical canal. Brachytherapy dose is the dose to point A using brachytherapy afterloading treatment based on external exposure dose, via a computer-controlled low dose rate source (40-70 cGy/h). The dose treatment should be individualized so that the tumor reaches an adequate therapeutic dose while considering the degree of normal tissue tolerance. the total dose to point A is the sum of external irradiation and brachytherapy. The new version of the Guidelines also makes slight adjustments to the treatment of stage IA1 and IA2 cervical cancer: for stage IA1 patients with vascular cancer embolism, “radical cervical hysterectomy plus pelvic lymph node dissection” is added; the treatment choice for stage IA2 patients is updated from “brachytherapy + pelvic radiotherapy” in 2010 to “brachytherapy + pelvic radiotherapy” in 2010. The treatment options for stage IA2 patients were updated from “brachytherapy + pelvic radiotherapy” to “brachytherapy ± pelvic radiotherapy” in 2010. Radical hysterectomy for cervical cancer with preserved fertility (radical hysterectomy) is suitable for patients with early-stage cervical cancer with fertility requirements, and the guideline updates its indications from “stage IA2 and stage IB1” to “stage IA1, stage IA2 and stage IB1 with tumor ≤2 cm in the vasculature. The new version of the Guidelines also updates the indications from “stage IA2 and IB1” to “stage IA1, stage IA2 and stage IB1 with tumor ≤2 cm”. In addition, the new version of the Guidelines also makes the following adjustments: pelvic contouring is limited to patients with central recurrence of cervical cancer, and no longer applies to those with non-central recurrence; retroperitoneal lymph node dissection is changed to extraperitoneal lymph node dissection for some patients with stage IB2, IIA2, IIB, IIIA, IIIB, and IVA with giant mass; chemotherapy for recurrent or metastatic cervical cancer is no longer advocated as platinum-based chemotherapy, but updated to chemotherapy; the category 1 evidence statement for cisplatin in combination with paclitaxel in first-line combination chemotherapy was removed, and minor adjustments were made to the second-line regimen. Ovarian Cancer The 2011 NCCN Clinical Practice Guidelines for Ovarian Cancer have been adjusted in the following areas Satisfactory tumor reduction is still defined as postoperative residual disease <1 cm, but with the addition of "resection of all visible lesions to the extent possible. Postoperative follow-up for ovarian cancer is recommended to be at least one pelvic examination at 2-3 cycles. The Phase III International Cooperative Ovarian Cancer Study Group 7 (ICON7), Gynecologic Oncology Collaborative Group 218 (GOG218) trial found that bevacizumab improved only progression-free survival (PFS) but not overall survival (OS) or quality of life in patients treated with first-line chemotherapy and maintenance therapy after ovarian cancer surgery. The addition of "pancreatic tail resection" to tumor reduction in ovarian cancer. In chemotherapy for platinum-resistant recurrent tumors, pemetrexed was changed from a drug of choice to a potentially effective agent.